ライフサイエンスコーパス: cardiac transplantation

1 rse clinical events (all-cause mortality and cardiac transplantation).

2 s explored risk factors for interim death or cardiac transplantation.

3 ents have died and 3 LQT3 patients underwent cardiac transplantation.

4 cular assist devices or potential donors for cardiac transplantation.

5 rdioprotection in a rat model of heterotopic cardiac transplantation.

6 rejection in a murine model of vascularized cardiac transplantation.

7 e not anastomosed to recipient lymphatics in cardiac transplantation.

8 after an ischemic time relevant to clinical cardiac transplantation.

9 e option for improving outcomes in pediatric cardiac transplantation.

10 t common cause of short-term mortality after cardiac transplantation.

11 f the TEA alone patients underwent an urgent cardiac transplantation.

12 8 eligible patients, nine patients underwent cardiac transplantation.

13 ence of viral endomyocardial infection after cardiac transplantation.

14 oronary artery 3.61 +/- 3.04 years following cardiac transplantation.

15 uality of life and lifespan of patients with cardiac transplantation.

16 ft dysfunction, and a higher mortality after cardiac transplantation.

17 heart failure severity and risk of death or cardiac transplantation.

18 months, the patient underwent a heterotopic cardiac transplantation.

19 mposite end point was all-cause mortality or cardiac transplantation.

20 of recipient RAAS polymorphisms in pediatric cardiac transplantation.

21 t ideal body weight <140%-before listing for cardiac transplantation.

22 apeutic target for allograft rejection after cardiac transplantation.

23 e, ejection fraction 18 +/- 8%) referred for cardiac transplantation.

24 ilure, GRK5-Leu41 protected against death or cardiac transplantation.

25 limiting factor in the long-term success of cardiac transplantation.

26 tive treatment, such as revascularization or cardiac transplantation.

27 ium iodide symporter (hNIS) gene transfer in cardiac transplantation.

28 (LVH) and diastolic dysfunction occur after cardiac transplantation.

29 r of who will require permanent pacing after cardiac transplantation.

30 endent heart failure patients ineligible for cardiac transplantation.

31 rtery lumen loss during the first year after cardiac transplantation.

32 t BNP interacts with the immune system after cardiac transplantation.

33 sufficiently while on therapy to qualify for cardiac transplantation.

34 ing and vessel remodeling, occur early after cardiac transplantation.

35 major cause of morbidity and mortality after cardiac transplantation.

36 onary lumen loss between years 1 and 2 after cardiac transplantation.

37 f myocardial recovery in patients bridged to cardiac transplantation.

38 Some patients may ultimately require cardiac transplantation.

39 diac-related hospitalization, or listing for cardiac transplantation.

40 opsy in the management of patients following cardiac transplantation.

41 ure (HF) patients and their implications for cardiac transplantation.

42 nt of death, hospitalization, or listing for cardiac transplantation.

43 , single ventricle physiology, and following cardiac transplantation.

44 ) is a major cause for late graft loss after cardiac transplantation.

45 ffect of donor HCV positivity on survival in cardiac transplantation.

46 5+ regulatory T cells either before or after cardiac transplantation.

47 nificant increases even up to 10 years after cardiac transplantation.

48 laxis against acute cellular rejection after cardiac transplantation.

49 sist devices (VADs) are important bridges to cardiac transplantation.

50 funding source to be considered eligible for cardiac transplantation.

51 monly used in the evaluation of patients for cardiac transplantation.

52 is the major cause of late graft failure in cardiac transplantation.

53 cause mortality, with censoring for interval cardiac transplantation.

54 ns for all cardiac operations in addition to cardiac transplantation.

55 biventricular failure and are candidates for cardiac transplantation.

56 t failure and influence clinical listing for cardiac transplantation.

57 in allograft rejection in a murine model of cardiac transplantation.

58 rom 10 patients with end-stage HF undergoing cardiac transplantation.

59 ion of bone loss during the first year after cardiac transplantation.

60 cardiac arrest in patients with a history of cardiac transplantation.

61 injury and graft coronary artery disease in cardiac transplantation.

62 tic parameters that determine the outcome of cardiac transplantation.

63 for the prevention of bone loss early after cardiac transplantation.

64 PCI) and the predictors for restenosis after cardiac transplantation.

65 n-associated renal toxicity in recipients of cardiac transplantation.

66 Osteoporosis is a well-known complication of cardiac transplantation.

67 vailable and the number of patients awaiting cardiac transplantation.

68 Eleven patients underwent cardiac transplantation.

69 tricular assist devices (VAD) as a bridge to cardiac transplantation.

70 ormal human valves (n=20) removed at time of cardiac transplantation.

71 curs in human subjects undergoing allogeneic cardiac transplantation.

72 fectively prevented T-cell alloreactivity in cardiac transplantation.

73 cardiac allograft vasculopathy (CAV), after cardiac transplantation.

74 CXCR3 mRNA persistently elevated after cardiac transplantation.

75 cardiac myocytes in hearts after orthotopic cardiac transplantation.

76 oglobin is an enhancer of inflammation after cardiac transplantation.

77 of available donor hearts continues to limit cardiac transplantation.

78 opathy is a common long-term complication of cardiac transplantation.

79 ed GCA and improving the long-term result of cardiac transplantation.

80 , ventricular assist device implantation, or cardiac transplantation.

81 ssist device (LVAD) placement as a bridge to cardiac transplantation.

82 e and function during tolerization in murine cardiac transplantation.

83 a growing problem in the field of pediatric cardiac transplantation.

84 ortant factor for morbidity and mortality in cardiac transplantation.

85 developed severe heart failure and underwent cardiac transplantation.

86 HC-mismatched models of allogeneic islet and cardiac transplantation.

87 tion is the major obstacle to survival after cardiac transplantation.

88 ded time to the combined outcome of death or cardiac transplantation.

89 ere were 52 deaths, and 7 patients underwent cardiac transplantation.

90 omposite of HF death, HF hospitalization, or cardiac transplantation.

91 eting in murine recipients in the context of cardiac transplantation.

92 ion, ventricular assist device insertion, or cardiac transplantation.

93 RIP3) mice to B6.C-H-2 (H2-Ab1; bm12) mouse cardiac transplantation.

94 he targeting of P2X7R a potential therapy in cardiac transplantation.

95 CM) remain at high risk of death or need for cardiac transplantation.

96 acting survival in the first 12 months after cardiac transplantation.

97 ticles on the volume-outcome relationship in cardiac transplantation.

98 the time of ISDC-therapy in a mouse model of cardiac transplantation.

99 ia, mandating single-ventricle palliation or cardiac transplantation.

100 roved cancer-free and overall survival after cardiac transplantation.

101 red from ischemic cardiomyopathy patients at cardiac transplantation.

102 tudy of ECG findings in potential donors for cardiac transplantation.

103 performed in a center and the outcome after cardiac transplantation.

104 ic manipulations for tolerance induction for cardiac transplantation.

105 e, end stage heart failure, and the need for cardiac transplantation.

106 tion therapy in those who are ineligible for cardiac transplantation.

107 The primary outcome was death or cardiac transplantation 12 months after randomization.

108 ve implantation of a heart failure device or cardiac transplantation (22% risk reduction, P=0.07).

109 of 12.2 years, 76 (29.1%) died, 5 (1.9%) had cardiac transplantation, 5 (1.9%) had Fontan revision, a

110 survival was 69%; 42 patients (84%) received cardiac transplantation, 5 patients (10%) were weaned, a

111 omly assigned 602 patients who had undergone cardiac transplantation 6 months to 5 years previously t

112 s with advanced heart failure as a bridge to cardiac transplantation, a bridge to recovery, and an al

113 For the first time since cardiac transplantation, a therapy is being developed to

114 sk of death, hospitalization, or listing for cardiac transplantation (adjusted hazard ratio, 63.6; P

115 to review the clinical course and outcome of cardiac transplantation after a failed Glenn or Fontan p

116 s to strongly predict all-cause mortality or cardiac transplantation after adjustment for traditional

117 points included cardiovascular mortality or cardiac transplantation; an arrhythmic composite of SCD

118 al rejection (HR) episodes occur early after cardiac transplantation and are associated with hemodyna

119 ial biopsy has defined rejection in clinical cardiac transplantation and established a threshold for

120 Two patients required cardiac transplantation and four died of cardiac failure

121 bjects who had undergone a gender-mismatched cardiac transplantation and had histological evidence of

122 sy has defined the diagnosis of rejection in cardiac transplantation and has historically been a vita

123 ek is effective prophylaxis after orthotopic cardiac transplantation and has prophylactic benefits ag

124 nt, hyperlipidemia remains problematic after cardiac transplantation and is associated with the devel

125 ctory to conventional pharmacologic therapy, cardiac transplantation and mechanical circulatory suppo

126 ill summarize the current state of pediatric cardiac transplantation and review recent advances leadi

127 Cardiac transplantation and sudden death were more preva

128 ts into the mechanisms of inflammation after cardiac transplantation and suggest that, in contrast to

129 icial heart improved the rate of survival to cardiac transplantation and survival after transplantati

130 with lumen loss during the first year after cardiac transplantation and that cytomegalovirus antibod

131 replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer pr

132 devices as a strategy to bridge patients to cardiac transplantation and, more recently, as a form of

133 ibers, 10-hr heart cold storage, heterotopic cardiac transplantation, and 24-hr reperfusion result in

134 se event-free survival from all-cause death, cardiac transplantation, and cardiac arrest (log-rank P=

135 were absence of sinus rhythm at enrollment, cardiac transplantation, and contraindications to colchi

136 zation, ventricular assist device placement, cardiac transplantation, and death.

137 n=23), normal human valves (n=20) removed at cardiac transplantation, and degenerative mitral valve l

138 All-cause mortality, cardiac transplantation, and HF hospitalization were tra

139 Death, cardiac transplantation, and HF hospitalization were tra

140 h advanced HF whose only previous option was cardiac transplantation, and it is now a realistic optio

141 events (all-cause mortality, cardiac death, cardiac transplantation, and MI) or major adverse cardio

142 The primary end point was death or cardiac transplantation, and secondary end points includ

143 Acute kidney injury is highly frequent after cardiac transplantation, and the stage of AKI is associa

144 h renal disease, children who have undergone cardiac transplantation, and those with aortic valve dis

145 phism, followed to the end point of death or cardiac transplantation, and transplant-free survival co

146 ly in childhood or adolescence or undergoing cardiac transplantation are affected by cardiomyopathies

147 sequences of acute kidney injury (AKI) after cardiac transplantation are scarce.

148 The causes of endothelial dysfunction after cardiac transplantation are unknown.

149 graft injury in the pre-engraftment phase of cardiac transplantation are warranted.

150 t of two recipient lists as a way to provide cardiac transplantation as an option to recipients who w

151 sure in 6 groups of animals (rat heterotopic cardiac transplantation) as follows: tobacco-naive allog

152 tant in the management of patients following cardiac transplantation, as non-invasive techniques are

153 lude destination therapy and alternatives to cardiac transplantation, as the supply of organs continu

154 cardiomyopathy and heart failure, requiring cardiac transplantation at ages 16 and 27.

155 Newly evaluated patients for cardiac transplantation at an academic medical center ge

156 100 patients (72 men and 28 women) receiving cardiac transplantation at our institution.

157 tients who should be considered too well for cardiac transplantation at specific stages of their dise

158 e heart failure in two sisters who underwent cardiac transplantation at three years of age.

159 arterial disease after total allomismatched cardiac transplantation (BALB/c donor heart and B6 recip

160 HO-1-derived CO prevents IRI associated with cardiac transplantation based on its antiapoptotic actio

161 re 2 late deaths because of RV failure and 1 cardiac transplantation because of progressive RV dysfun

162 ompatibility complex class II allomismatched cardiac transplantation (bm12 donor heart and B6 recipie

163 After cardiac transplantation, both cell types showed drastic

164 lished surgical therapy for heart failure is cardiac transplantation, but its impact is limited due t

165 has examined this relationship in pediatric cardiac transplantation, but low-volume adult heart tran

166 Anti-ICAM-1 antibodies are produced after cardiac transplantation, but not to polymorphic residues

167 Progression of heart failure can lead to cardiac transplantation, but when patients are ineligibl

168 associated with cardiovascular mortality or cardiac transplantation (by fibrosis presence: HR, 3.22

169 Cardiac transplantation can be performed successfully in

170 rgoing right heart catheterization to assess cardiac transplantation candidacy (N=141).

171 c transplantation evaluation in a designated cardiac transplantation center.

172 alapril therapy had either died or undergone cardiac transplantation, compared with three of the 12 a

173 remained stable during the second year after cardiac transplantation, despite a significant increase

174 Depletion of recipient cDCs after cardiac transplantation drastically decreased presentati

175 eurohormonal blockade, and (7) no structured cardiac transplantation evaluation in a designated cardi

176 d 238 patients with advanced HF referred for cardiac transplantation evaluation who had cTnI assay dr

177 This demonstrates that cardiac transplantation followed by ASCT is feasible in

178 management of an infant who had heterotopic cardiac transplantation for advanced cardiomyopathy with

179 Cardiac transplantation for amyloid patients with extend

180 with LQTS after birth, ultimately requiring cardiac transplantation for control of ventricular tachy

181 evaluated adults who underwent single-organ, cardiac transplantation from 1994 to 2009 with a diagnos

182 After cardiac transplantation, graft damage occurs secondary t

183 Cardiac transplantation has become a standard therapeuti

184 also discuss how the funding requirement for cardiac transplantation has been addressed by the federa

185 The role for LVADs as a bridge to cardiac transplantation has been established, but data s

186 prevention of toxoplasmosis after orthotopic cardiac transplantation has been the subject of some con

187 gh aggressive medical therapy and ultimately cardiac transplantation have long been the therapeutic m

188 Improvements in early mortality after cardiac transplantation have occurred consistently over

189 ure death, heart failure hospitalization, or cardiac transplantation (hazard ratio, 2.70; 95% CI, 1.3

190 dary outcomes of cardiovascular mortality or cardiac transplantation (hazard ratio, 3.35; 95% CI, 1.7

191 g alloreactivity and high-grade rejection in cardiac transplantation; however, its efficacy seemed to

192 use, lifesaving cardiovascular intervention (cardiac transplantation, implantation of a ventricular a

193 come occurred in 55, with death in 24 (23%), cardiac transplantation in 18 (17%), and clinical decomp

194 Liver transplantation immediately preceded cardiac transplantation in 2 of the 27 cases because of

195 lymphatic flow index following heterotrophic cardiac transplantation in a murine model of chronic rej

196 of the systemic right ventricle necessitates cardiac transplantation in a subset of patients.

197 t common form of cardiomyopathy and cause of cardiac transplantation in children.

198 test this concept, 20 subjects who underwent cardiac transplantation in infancy and healthy age-match

199 al issues relating to the use of heterotopic cardiac transplantation in infants and the capacity of t

200 For cardiac transplantation in infants, T cells are depleted

201 However, when antibodies are low, in cardiac transplantation in neonates for example, no dese

202 alovirus (CMV) replication is frequent after cardiac transplantation in recipients with pretransplant

203 of 14 mg x kg(-1) x min(-1) for referral for cardiac transplantation in these patients requires reeva

204 hepatic associations and the role for early cardiac transplantation in this population is critical.

205 used complementary murine models of skin and cardiac transplantation in which prolonged allograft acc

206 one of the indicators used to optimally time cardiac transplantation in women.

207 is a leading cause of heart failure (HF) and cardiac transplantations in Western countries.

208 ent mice had exaggerated immune responses to cardiac transplantation, including increased numbers of

209 ses in a non-BCR-transgenic model of C57BL/6 cardiac transplantation into BALB/c recipients treated w

210 Cardiac transplantation is a life-saving procedure in in

211 Cardiac transplantation is also discussed.

212 Cardiac transplantation is an accepted therapy for patie

213 Cardiac transplantation is an effective therapy for end-

214 Cardiac transplantation is an excellent treatment for en

215 The development of fibrosis after cardiac transplantation is associated with advanced coro

216 CMV replication after cardiac transplantation is associated with chronic endot

217 nagement, especially for individuals in whom cardiac transplantation is indicated.

218 Survival after cardiac transplantation is markedly reduced due to the p

219 re of the lymphatics, the function following cardiac transplantation is poorly understood.

220 Cardiac transplantation is the definitive treatment for

221 Cardiac transplantation is the most effective treatment

222 If other therapies are ineffective, cardiac transplantation is the only therapeutic recourse

223 ion causes heart failure, but its role after cardiac transplantation is unclear.

224 The prognosis for patients with ACM after cardiac transplantation is unknown.

225 myocardial ischemic injury within 2 weeks of cardiac transplantation (ischemia group).

226 with the continuing organ donor shortage for cardiac transplantation, left ventricular assist devices

227 c neovascularization, we used an established cardiac transplantation model and showed that unlike wil

228 In a rat cardiac transplantation model coadministration of a none

229 Studies in a murine cardiac transplantation model demonstrated that synergis

230 The mouse heterotopic cardiac transplantation model has been used extensively

231 We show in a mouse cardiac transplantation model that antidonor immune resp

232 A murine heterotopic cardiac transplantation model was used to test whether r

233 heterotopic (abdominal) vascularized murine cardiac transplantation model.

234 ated the establishment of fully vascularized cardiac transplantation models in small mammals.

235 ntricular Assist System [LVAS] for Bridge to Cardiac Transplantation; NCT00121472).

236 sk stratification for all-cause mortality or cardiac transplantation (net reclassification improvemen

237 r or implantable cardioverter-defibrillator, cardiac transplantation, new heart failure, stroke, or o

238 Cardiac transplantation of angiogenic EOCs from healthy

239 (LVADs) are increasingly used as a bridge to cardiac transplantation or as destination therapy.

240 ve disease that resulted in the necessity of cardiac transplantation or in death.

241 time to, adverse outcome, defined as death, cardiac transplantation, or clinical decompensation requ

242 well as long-term clinical outcomes (death, cardiac transplantation, or HF hospitalization).

243 Primary end points were death, cardiac transplantation, or hospitalization.

244 outcomes: 1) the combined endpoint of death, cardiac transplantation, or ventricular assist device (V

245 its performance in predicting risk of death, cardiac transplantation, or ventricular assist device pl

246 Subjects were followed for death, cardiac transplantation, or ventricular assist device pl

247 te the increasing use of LVAD as a bridge to cardiac transplantation, our knowledge regarding its eff

248 ssociated with an increased risk of death or cardiac transplantation over a median follow-up of 2.4 y

249 29) or with increasing duration of time from cardiac transplantation (P = 0.0874).

250 safety of neostigmine and glycopyrrolate in cardiac transplantation patients.

251 Retrospective chart review queried cardiac transplantations performed at our institution fr

252 ssess the relationship between the volume of cardiac transplantation procedures performed in a center

253 Cardiac transplantation remains the gold standard of sur

254 Cardiac transplantation remains the treatment of last re

255 , volatile anesthesia and hypothermia during cardiac transplantation remains to be established.

256 than three decades of clinical experience in cardiac transplantation resulted in the spread of the pr

257 tar Furth iMDCs, unlike mMDCs, 7 days before cardiac transplantation significantly prolonged graft su

258 ost of the pericardial effusions occurred in cardiac transplantation, sirolimus is not approved for t

259 he areas of left ventricular assist devices, cardiac transplantation, strain-rate echocardiography, a

260 rogenitor cells (EPCs) were quantified in 15 cardiac transplantation subjects with and without angiog

261 els in failing human hearts retrieved during cardiac transplantation surgery.

262 eart failure; the tissue was obtained during cardiac transplantation surgery.

263 s who eventually may require transplantation.Cardiac transplantation survival has improved, but morbi

264 alendronate or calcitriol immediately after cardiac transplantation sustained minimal bone loss duri

265 Hospitals without cardiac transplantation that serve high-acuity HF patien

266 f 5 subjects who underwent gender-mismatched cardiac transplantation, there was a significant seeding

267 ular recovery or as a bridge for patients to cardiac transplantation, these devices are now being use

268 plication of peak VO2 as an aid to determine cardiac transplantation timing should be re-examined.

269 ression and surgical techniques have allowed cardiac transplantation to become a viable option and th

270 -stage heart failure who were ineligible for cardiac transplantation to receive a left ventricular as

271 ally altered mice in an established model of cardiac transplantation to study the role of MHC and co-

272 ession analyses were performed, censoring at cardiac transplantation, to assess the impact of preoper

273 In three infants awaiting orthotopic cardiac transplantation, transplantation was successfull

274 sirolimus versus azathioprine treatment in a cardiac transplantation trial (28.6% versus 9.3%, respec

275 aque progression during the first year after cardiac transplantation (Tx) is unknown.

276 An interdisciplinary protocol for cardiac transplantation using extended-donor criteria or

277 This study investigates the outcomes of cardiac transplantation using older donors.

278 Cardiac transplantation vasculopathy is the leading caus

279 itigates inflammatory and immune sequelae of cardiac transplantation via the A(2B)AR.

280 The interval risk of death or/cardiac transplantation was associated with poorer ventr

281 HC class I and II mismatched murine model of cardiac transplantation was developed (bm12.Kd.IE to C57

282 Primary orthotopic cardiac transplantation was performed in 35 patients (me

283 Intra-abdominal cardiac transplantation was performed using C57BL/10 mic

284 primary end point of all-cause mortality or cardiac transplantation was reached by 42 of 86 patients

285 Pacing was required in 70%; cardiac transplantation was required in 4 children.

286 A murine model of cardiac transplantation was used (bm12.Kd.IE to C57BL/6)

287 EFECT (EFfect of Etanercept on Cardiac Transplantation) was a randomized, controlled, d

288 Using a murine model of MHC-mismatched cardiac transplantation, we investigated the influence o

289 Using a model of murine cardiac transplantation, we now demonstrate that allorea

290 While studying Th responses induced by cardiac transplantation, we observed that mice deficient

291 hymocyte globulin (mATG) in a mouse model of cardiac transplantation, we previously showed that perit

292 Using a mouse model of cardiac transplantation, we show that when Listeria mono

293 METHODS AND Using heterotopic rat cardiac transplantation, we tested the effects of donor

294 Overall, cardiac mortality and the need for cardiac transplantation were low (6% and 4%, respectivel

295 spective study, 40 patients (0-2 years after cardiac transplantation) were randomly assigned vitamin

296 Patients <25 years of age, after cardiac transplantation, were enrolled (2003 to 2008) an

297 n in renal function is frequently seen after cardiac transplantation, which is partly explained by th

298 Coronary arteries from patients undergoing cardiac transplantation with CAD or without CAD were stu

299 However, BNP behaves unusually after cardiac transplantation, with a failure to return to nor

300 tients will be rehospitalized and/or require cardiac transplantation within 1 year of admission.